DILUMEN™ EIP COMPLETES 100 THERAPEUTIC PROCEDURES ACROSS UNITED STATES

WESTPORT, CONN, DECEMBER 6, 2017 − Connecticut-based medical device innovator Lumendi, LLC reports it has successfully completed more than 100 therapeutic procedures with its DiLumen™ EIP technology, demonstrating the safety, performance and therapeutic benefits of DiLumen.  These procedures are in addition to those in its first-in-human trial completed in October 2017. The DiLumen™ EIP, which received FDA 510K clearance to market in December 2016 and has been commercially available in the United States since May 2017, has been used by an estimated 30 advanced endoscopists and colorectal surgeons across the country.

“With more extensive use of DiLumen, its true potential is being realized, validating our goal of shifting the paradigm for colon disease intervention from the traditional surgical approach to a truly minimally invasive one that utilizes novel endolumenal-based technology. This shift will increase safety and patient recovery time as well as significantly reduce costs,” said Dr. Peter Johann, CEO of Lumendi, Ltd.

The DiLumen Endolumenal Interventional Platform (EIP) is a non-sterile, single-use, close-fitting sleeve that fits securely over a standard endoscope to stabilize it in the large intestine and facilitates use of the endoscope for optical visualization, diagnosis, and treatment. The device was developed by Lumendi in collaboration with the Minimally Invasive New Technologies Program (MINT) at Weill Cornell Medicine and New York-Presbyterian. It is the first device from the Endolumenal Interventional Platform based on Lumendi and MINT’s initiative to migrate many gastrointestinal surgeries to endolumenal procedures.